Untitled

Artificial intelligence is helping researchers turn increasingly complex biological data into more meaningful and actionable insights. BostonGene’s recognition at the 2026 AI Breakthrough Awards highlights the potential of AI-driven analytics to support biomarker development, improve patient selection, and reduce uncertainty when making important decisions throughout the oncology drug development process.

Artificial intelligence is transforming clinical research by helping researchers better understand complex patient biology and make more informed decisions throughout the drug development process. At BIO 2026, BostonGene will showcase how its AI-powered solutions integrate molecular, cellular, and clinical data to improve patient selection, optimize clinical trial design, and predict treatment outcomes. By turning complex biological data into actionable insights, these innovations are helping accelerate precision medicine, reduce clinical trial risks, and support the development of more personalized therapies across oncology.

BostonGene will present its latest AI foundation models at the 22nd Annual RadMed Symposium, highlighting how multimodal AI and blood-based immune profiling are helping predict immunotherapy response, assess toxicity risk, and improve patient stratification. The session will demonstrate how AI-driven insights can accelerate precision oncology research and support smarter drug development.

As drug development becomes increasingly complex, the need for more informed decision-making has never been greater. By leveraging multimodal AI and advanced biological modeling, organizations can gain deeper insights into disease mechanisms, optimize patient selection and improve clinical trial design.

Integrating genomic, clinical, immune and imaging data enables researchers to move beyond retrospective analysis and make more predictive, data-driven decisions earlier in the development process. This approach has the potential to reduce risk, improve trial outcomes and accelerate the delivery of innovative therapies to patients.

Industry recognition continues to highlight the growing role of AI in transforming oncology research and reshaping the future of precision medicine.

BostonGene will present six research abstracts at EHA 2026, highlighting how AI-powered multiomics analysis and immune profiling are transforming blood cancer research. Developed in collaboration with leading cancer centers and academic institutions, these studies demonstrate the potential of predictive modeling, biomarker discovery, and integrated genomic analysis to improve risk stratification, predict treatment response, and support more personalized therapeutic strategies. The findings reinforce the growing role of AI in advancing precision medicine and optimizing clinical decision-making in hematologic malignancies.

BostonGene is showcasing new research at ASCO 2026 that demonstrates the clinical value of AI-powered models and comprehensive molecular profiling in oncology. The presented studies highlight innovative approaches to biomarker discovery, treatment response prediction, and patient stratification, helping advance precision medicine and improve outcomes across multiple cancer types.

BostonGene has been recognized at the 2025 Life Sciences Times Vanguard Awards for its innovative approach to oncology drug development. The company’s AI-powered platform combines data from tumor and immune biology to help researchers better understand how treatments may work before they reach patients. By supporting smarter trial design and faster decision-making, BostonGene is helping make the drug development process more efficient and focused.

A new research collaboration between academia and AI-driven technology is helping advance precision oncology by combining molecular, genomic and immune profiling insights to support more personalized cancer treatment approaches. The initiative focuses on transforming complex clinical and biological data into actionable insights that can help improve therapeutic decision-making and support future oncology research.

BostonGene has received recognition from Frost & Sullivan for its contribution to AI-driven oncology innovation. The company’s multimodal platform supports biopharma teams by analyzing complex biological and clinical data to improve trial design, biomarker strategies, and patient selection in cancer treatment research.

The recognition reflects the growing role of AI and data-driven technologies in helping researchers make faster and more informed decisions throughout the drug development process.

BostonGene and Unilever are working together to explore how AI and multiomics can support scientific research and deepen the understanding of human biology. The collaboration combines data integration, analytics, and scientific expertise to study biological variation and identify insights that may contribute to future consumer research and product development. It also highlights the increasing use of AI in broader areas of scientific exploration and innovation.

BostonGene is presenting its AI-powered disease modeling platform at JSMO 2026, highlighting how multimodal data and foundation models are improving drug development and clinical decision-making. By enabling better patient stratification and therapy insights, the platform is helping advance precision oncology and supporting collaborations with leading biopharma companies.

BostonGene is working with ImmunoGenesis to study IMGS-001, a therapy under evaluation in the NCT06014502 trial for solid tumors. The collaboration uses AI-based multiomic analysis and spatial biology to examine how treatments interact with both tumors and the immune system. By focusing on detailed biological data from individual patients, the research aims to improve understanding of treatment response and support more informed clinical decisions.

BostonGene will present 13 abstracts at the AACR Annual Meeting 2026, highlighting its advanced AI platform for tumor and immune biology. The presentations demonstrate how AI-driven multiomic analysis is accelerating drug discovery, improving patient stratification, and reducing risks in clinical development.

BostonGene, in collaboration with The University of Texas MD Anderson Cancer Center, shares results from a prospective study demonstrating how RNA transcriptome profiling can reveal new therapeutic targets in advanced solid tumors. By integrating RNA expression with DNA sequencing and AI-powered multiomic analysis, the research highlights how previously hidden treatment opportunities can be identified, especially for patients who lacked actionable insights from DNA testing alone. The findings also point to the growing importance of antibody-drug conjugates (ADCs) and comprehensive molecular profiling in expanding precision oncology approaches and enabling more personalized treatment strategies.

BostonGene has been honored with the 2025 Global Technology Innovation Leadership recognition by Frost and Sullivan for its AI driven precision oncology solutions.

The company’s omnimodal foundation model integrates multiple layers of biological and clinical data to deliver insights that support biomarker strategies, improve patient selection and enhance therapeutic development.

By enabling more data driven decision making, BostonGene is helping accelerate clinical trials and increase efficiency in oncology drug development.

Artificial intelligence continues to play a major role in accelerating cancer research and therapeutic innovation. BostonGene has partnered with Ottimo Pharma to support development of a first in class PD1 and VEGFR2 immuno oncology therapy.

The collaboration leverages advanced analytics and multiomic insights to improve clinical research strategies and support next generation precision oncology treatments.